Identification
and validation
of new therapeutic
targets



Helios Biosciences - Target Designer

Our R&D Program
Prostate Cancer
Immuno-dyn

Company Presentation (PDF)
WhitePaper (PDF)

European Projects
Valapodyn (Website, Brochure)
Tempo (Website)
Inflacare (Website)

Contact Us

Helios BioSciences
102, avenue Gaston Roussel
93230 Romainville
France
Phone : +33 (0)157 148 396
Fax : +33 (0)972 314 803
Contact




January 2010

Year 2009 overview

During year 2009 :

  • a. We have improved the efficiency of our plateform of analysis of Tissular and Cellular Expression (TCE). We now routinely work with paraffin embedded slices and realize immuno-histochemistry and/or in situ hybridization on this material.
  • b. We decided to focus our resources on the validation of 3 of the 6 immunosuppressives targets that were selected with our Dynamic Model IMMUNODYN. We have designed peptides inhibiting the interactions between these targets. Thee peptides are used to transfect Lymphocytes. The cytokine profile and the proliferation rate of the lymphocytes are determined.
  • c. During the last quarter our technology of modeling has started to be evaluated by potential customers. These evaluation should be completed during the second semester of 2010.















[Page top] - [Legal Notice & Credits]

nav